炎症性疾病生物技术公司Invea Therapeutics(INAI.US)撤回3500万美元IPO计划

Core Viewpoint - Invea Therapeutics has withdrawn its initial public offering (IPO) plan due to market conditions, which was aimed at raising $35 million by offering 3.2 million shares at a price range of $10 to $12 per share [1] Company Overview - Invea Therapeutics is a clinical-stage biotechnology company focused on developing oral small molecule drugs for inflammatory diseases [1] - The company was founded in 2021 and is headquartered in Guilford, Connecticut [1] IPO Details - The company had planned to list on NASDAQ under the ticker symbol INAI [1] - ThinkEquity was set to be the exclusive bookrunner for the IPO [1]